Cover Image

Single-dose liposomal amphotericin B: an effective treatment for visceral leishmaniasis

Saved in:

Bibliographic Details
Main Authors:	Prabhat Kumar Sinha (Author), Sujit Bhattacharya (Author)
Format:	Book
Published:	Elsevier, 2014-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Single-dose liposomal amphotericin B for visceral leishmaniasis
by: Nilima A Kshirsagar
Published: (2014)

Different liposomal amphotericin B formulations for visceral leishmaniasis
by: Thomas P C Dorlo, et al.
Published: (2014)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
by: Gloria Morizot, et al.
Published: (2016)

Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh.
by: Emiliano Lucero, et al.
Published: (2015)

Different liposomal amphotericin B formulations for visceral leishmaniasis-Author's reply
by: Nilima Kshirsagar
Published: (2014)

Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
by: Sakib Burza, et al.
Published: (2014)

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).
by: Sakib Burza, et al.
Published: (2014)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
by: Andrew A Voak, et al.
Published: (2021)

Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study
by: Dr. Dinesh Mondal, PhD, et al.
Published: (2014)

Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.
by: Sakib Burza, et al.
Published: (2014)

Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.
by: Sakib Burza, et al.
Published: (2014)

Visceral Leishmaniasis in Children in Southern Turkey: Evaluation of Clinical and Laboratory Findings and Liposomal Amphotericin B Treatment
by: Barbaros Şahin Karagün, et al.
Published: (2019)

Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.
by: Shyam Sundar, et al.
Published: (2014)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
Published: (2014)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India.
Published: (2014)

Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India.
by: Michaela Fakiola, et al.
Published: (2019)

Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
by: Romain Guery, et al.
Published: (2017)

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes
by: Guilherme S. Ramos, et al.
Published: (2022)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
Published: (2014)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India.
Published: (2014)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
by: Charles Abongomera, et al.
Published: (2018)

Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies
by: Mudavath SL, et al.
Published: (2014)

Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations
by: Frédéric Frézard, et al.
Published: (2022)

Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis
by: Vahid Mashayekhi Goyonlo, et al.
Published: (2014)

Safety Evaluation of Nano-Liposomal Formulation of Amphotericin B (SinaAmpholeish) in Animal Model as a Candidate for Treatment of Cutaneous Leishmaniasis
by: Seyed Ebrahim Eskandari, et al.
Published: (2018)

Pharmacotherapeutic Options for Visceral Leishmaniasis-Current Scenario
by: Krishna Pandey MD, et al.
Published: (2009)

Comparison of the Efficacies of Topical Liposomal Amphotericin B and Topical Clotrimazole in the Treatment of Pityriasis Versicolor
by: Mehdi Ghahartars, et al.
Published: (2024)

A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh.
by: Shyam Sundar, et al.
Published: (2024)

Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of Cutaneous leishmaniasis
by: Adnan Anjum, et al.
Published: (2023)

Local amphotericin B therapy for Cutaneous Leishmaniasis: A systematic review.
by: Líndicy Leidicy Alves, et al.
Published: (2024)

A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India
by: Vidya N, et al.
Published: (2008)

A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.
by: Ellen K Wasan, et al.
Published: (2010)

Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.
by: Eltahir A G Khalil, et al.
Published: (2014)

Amphotericin B release rate is the link between drug status in the liposomal bilayer and toxicity
by: Yuri Svirkin, et al.
Published: (2022)

Persistent dyselectrolytemia in a neonate induced by liposomal amphotericin B. A case report
by: Adrian Puertas Sanjuan, et al.
Published: (2023)

Preparation, Characterization, and In Vivo Pharmacokinetic Study of the Supercritical Fluid-Processed Liposomal Amphotericin B
by: Chang-baek Lim, et al.
Published: (2019)

Comparison of efficacy of two different concentrations of intralesional amphotericin B in the treatment of cutaneous leishmaniasis; A randomized controlled trial
by: Pooja Goswami, et al.
Published: (2019)

Pharmacokinetics, Dose-Proportionality, and Tolerability of Intravenous Tanespimycin (17-AAG) in Single and Multiple Doses in Dogs: A Potential Novel Treatment for Canine Visceral Leishmaniasis
by: Marcos Ferrante, et al.
Published: (2024)

Therapeutic and Prophylactic Effects of Amphotericin B Liposomes on Chronic Social Defeat Stress-Induced Behavioral Abnormalities in Mice
by: Jiashu Lu, et al.
Published: (2022)

A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy.
by: Smriti Mondal, et al.
Published: (2010)